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Abstract: Antimicrobial peptides (AMPs) have been an area of great interest, due to the high
selectivity of these molecules toward bacterial targets over host cells and the limited development
of bacterial resistance to these molecules throughout evolution. The peptide C18G has been shown
to be a selective, broad spectrum AMP with a net +8 cationic charge from seven lysine residues
in the sequence. In this work, the cationic Lys residues were replaced with other natural or
non-proteinogenic cationic amino acids: arginine, histidine, ornithine, or diaminopropionic acid.
These changes vary in the structure of the amino acid side chain, the identity of the cationic
moiety, and the pKa of the cationic group. Using a combination of spectroscopic and microbiological
methods, the influence of these cationic groups on membrane binding, secondary structure, and
antibacterial activity was investigated. The replacement of Lys with most other cationic residues
had, at most, 2-fold effects on minimal inhibitory concentration against a variety of Gram-positive
and Gram-negative bacteria. However, the peptide containing His as the cationic group showed
dramatically reduced activity. All peptide variants retained the ability to bind lipid vesicles and
showed clear preference for binding vesicles that contained anionic lipids. Similarly, all peptides
adopted a helical conformation when bound to lipids or membrane mimetics, although the peptide
containing diaminopropionic acid exhibited a decreased helicity. The peptides exhibited a wider
variety of activity in the permeabilization of bacterial membranes, with peptides containing Lys,
Arg, or Orn being the most broadly active. In all, the antibacterial activity of the C18G peptide
is generally tolerant to changes in the structure and identity of the cationic amino acids, yielding
new possibilities for design and development of AMPs that may be less susceptible to immune and
bacterial recognition or in vivo degradation.
Keywords: antimicrobial peptides; fluorescence; lipid binding; non-natural amino acids

1. Introduction
The continued development and spread of antibiotic resistance is a major concern, with the World
Health Organization (WHO) and the United States Centers for Disease Control (CDC) identifying
antibiotic resistance as a major health threat in the coming years [1,2]. Patients who become infected
with resistant strains of bacteria often require longer hospital stays or treatments, therefore increasing
the total cost of therapy [3,4]. Due to the rapid life cycle of bacteria and pursuant random mutations or
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genetic alterations, as well as improper use of existing antibiotics, bacteria have many advantages in
acquiring resistant phenotypes. Additionally, many pathogenic bacteria can form biofilm structures
that create an additional permeability barrier to antimicrobial therapeutics [5,6].
The rise of antimicrobial resistance not only underscores the need for development of new
antimicrobial compounds, but also highlights the necessity to develop new compounds with lower
potentials for development of resistance. Many approaches have been taken in the development of
new or improved antimicrobials, including combinatorial therapies [7,8], biomolecule mimetics [9,10],
natural products [11,12], synthetic polymers [13,14], metals and metal complexes [15], quorum sensing
inhibitors [16,17], and antimicrobial peptides (AMPs) [18]. AMPs have been an area of extensive study,
as they are relatively straightforward to synthesize and characterize, biologically and evolutionarily
diverse, and show little evidence of resistance development throughout evolution. Generally, AMPs
are cationic, amphiphilic peptides that exhibit high selectivity for bacterial targets over host cells.
This selectivity arises from the net positive charge on the AMPs and the net negative surface charge of
the bacterial target cells, as opposed to the net neutral charge of the mammalian or host cell membrane.
However, there is little in the way of consensus sequences or structural motifs that are conserved
throughout this class of peptides [19]. Nonetheless, cationic, helical AMPs are among the most widely
found in nature, and widely studied [20,21]. These molecules are relatively short (less than 40aa),
contain a mix of hydrophobic and cationic amino acids, and often adopt a facially-amphiphilic helical
structure when bound to the lipid bilayer or bacterial membrane. The consensus in the literature is that
these AMPs act by permeabilizing the bacterial membrane, but there are reports of other mechanisms
as well, including DNA damage [22] and oxidative stress or damage [23]. There are also numerous
reports of AMPs acting through an immunomodulatory role [24,25]. The proposed mechanism of
membrane disruption is through the partitioning of the hydrophobic helical face into the bilayer
core, disrupting lipid packing and creating transient pores that allow leakage of content across the
membrane [26].
One interesting example of the helical AMPs is the peptide C18G. This peptide was originally
derived from the C-terminal 13 amino acids of platelet factor IV and modified to enhance the
activity [27,28]. The C18G peptide exhibits broad spectrum activity, with high selectivity for bacterial
cells over host cells, and generally low toxicity to host cells. The peptide sequence is inherently
interesting, as the majority of the 18 residues are either Leu or Lys, with all of the cationic charge
arising from Lys and all of the hydrophobic character coming from Leu. Subsequently, C18G was
found to interact with several two-component signaling systems in bacteria, identifying these proteins
as potential AMP sensors in addition to the original ligands Mg+2 [29,30], ferric iron (Fe+3 ), aluminum
(Al+3 ), or pH [31]. More recently, the role of the hydrophobic amino acids in C18G was investigated
by replacing all the Leu residues with other hydrophobic amino acids. This study demonstrated that
hydrophobicity alone does not determine the activity of the peptides, and that the structure of the
hydrophobic amino acid side chain plays a significant role in membrane permeabilization activity [32].
Despite the previous work on C18G and AMPs in general, there is still no consensus on the
molecular determinants of activity. While the hydrophobic groups influence the activity of the
peptide, there have been no reports in the literature investigating the role of the cationic amino
acids in the peptide behavior. In the work presented here, the Lys residues were systematically
replaced with either arginine, histidine, ornithine (Orn, O), or diaminopropionic acid (Dap, X).
The Arg and His residues were chosen as they are the other naturally occurring cationic amino
acids, while Orn and Dap were selected as they retain the primary amino group of Lys, but alter the
side chain length, potentially altering the membrane penetration depth or the 3-D topography of the
peptide when bound to the membrane surface. Using a combination of fluorescence spectroscopy
and circular dichroism spectroscopy, the interactions of the peptides with model lipid vesicles were
investigated. The membrane permeabilizing activity of the peptides was then investigated using
enzyme based bacterial membrane permeabilization assays, flow cytometry, and red blood cell
hemolysis experiments.

Molecules 2018, 23, 329
Molecules 2018, 23, x

3 of 17
3 of 16

2. Results

2. Results

2.1. Peptide Sequences and Structure

2.1. Peptide Sequences and Structure

The original C18G sequence and a number of sequence variants have been previously shown
The
a number
of sequencemimetics
variants have
previously
to of
to adopt
anoriginal
α-helix C18G
whensequence
bound toand
bilayers
or membrane
[32]. been
A helical
wheelshown
diagram
adopt an ⍺-helix when bound to bilayers or membrane mimetics [32]. A helical wheel diagram of
C18G is shown in Figure 1A. The helical conformation of C18G, and all of the cationic variants in this
C18G is shown in Figure 1A. The helical conformation of C18G, and all of the cationic variants in this
report, adopt a facially amphiphilic helical structure, with cationic residues segregated to one face of
report, adopt a facially amphiphilic helical structure, with cationic residues segregated to one face of
the helix and the hydrophobic groups segregated to the opposite face of the helix. As the focus of this
the helix and the hydrophobic groups segregated to the opposite face of the helix. As the focus of this
work is on the cationic amino acids, the structures of the cationic side chains are shown in Figure 1B,
work is on the cationic amino acids, the structures of the cationic side chains are shown in Figure 1B,
andand
peptide
sequences
Table 1.
1.
peptide
sequencesininthis
thisstudy
studyare
areshown
shown in
in Table

Figure 1. Peptide and amino acid structures. The C18G sequence is depicted in a helical wheel
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Table 1. Peptide Sequences.
Name

Sequence

Net Charge a

MW (Da)

MW (Da) Found

C18G
C18G-Arg
C18G-His
C18G-Orn
C18G-Dap

ALWKKLLKKLLKSAKKLG
ALWRRLLRRLLRSARRLG
ALWHHLLHHLLHSAHHLG
ALWOOLLOOLLOSAOOLG
ALWXXLLXXLLXSAXXLG

+8
+8
+1 b
+8
+8

2065.7
2261.8
2128.5
1967.7
1771.7

2065.4
2261.5
2128.2
1967.3
1771.1

a

Net charge includes the 7 cationic residues plus the free N-terminus. The C-terminus of the peptide is amidated;
The pKa of the His side chain is 6.04, therefore ~90% of His side chains are predicted to be neutral at pH 7,
where experiments were performed.
b

2.2. Antibacterial Activity Assays
The cationic variants of C18G were first assessed for the ability to inhibit bacterial growth in the
standard minimum inhibitory concentration (MIC) assay. The results of the MIC assay are shown in
Table 2. There were several notable results from this analysis, the foremost being that the C18G-Dap
peptide exhibited at most a 4-fold increase in MIC (against Staphylococcus aureus (S. aureus)) but in
two cases, identical MICs (Bacillus subtilis (B. subtilis) and Pseudomonas aeruginosa (P. aeruginosa)) to
the parent sequence. Interestingly, the C18G-His peptide showed significantly reduced antibacterial
activity against most of the strains tested, but very similar MIC values to the other peptides when
challenged with Escherichia coli (E. coli) or B. subtilis. The minimal bactericidal concentration (MBC)
values, when able to be determined, were no more than 2-fold higher than the MIC value in all
cases, except C18G-His against B. subtilis. These results indicate that the peptides are acting through
a bactericidal mechanism, rather than a bacteriostatic mechanism.
Table 2. Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) (µM).
E. coli

C18G
C18G-Arg
C18G-His
C18G-Orn
C18G-Dap

P. aeruginosa

A. baumannii

S. aureus

B. subtilis

MIC

MIC

MBC

MIC

MBC

MBC

MIC

MBC

MIC

MBC

1.875
1.875
3.75
1.875
3.75

7.5
7.5
>15
3.75
7.5

7.5
7.5
>15
3.75
7.5

15
>15
>15
3.75
7.5

1.875
3.75
>15
1.875
3.75

n.d.
7.5
>15
1.875
3.75

1.875
3.75
15
1.875
7.5

3.75
3.75
15
1.875
7.5

1.875
1.875
1.875
3.75
1.875

1.875
1.875
>15
7.5
1.875

n.d.—not determined

2.3. Binding to Lipid Vesicles
Based on the proposed mechanism of membrane disruption, the ability of the C18G peptides to
interact with lipid vesicles was investigated. All of the sequences contain a Trp residue which can
be used as a reporter of the local environment. As the peptide moves from the aqueous milieu to
the bilayer surface, the Trp experiences a significant change in the polarity of the local environment.
This change in environmental polarity results in a shift of the Trp emission spectrum from more
red-shifted (aqueous) to more blue-shifted (bilayer bound) [32]. Similarly, the depth of the Trp in
the bilayer also affects the emission spectrum, with increasing depth in the bilayer resulting in more
extensive blue shifting [33]. The shift in the emission spectrum can be quantified by changes in
maximum emission intensity (λmax ) or by a shift in the spectral barycenter [32,34,35].
As judged by the shift in the emission barycenter, the peptides all exhibited the ability
to bind to lipid vesicles that were composed of 3:1 1,2-dioleoyl-sn-glycero-3-phosphocholine/
1,2-Dioleoyl-sn-glycero-3-phosphoglycerol (PC/PG) lipids (Figure 2A). The PG lipid headgroup
contains a net negative charge, mimicking the net anionic surface charge of bacterial cells. In all cases,
the peptides exhibited a significant change in the emission spectrum upon addition of lipid vesicles.
There was considerably weaker binding to vesicles composed of 100% PC lipids, consistent with
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β-lactamase and the chromogenic substrate nitrocefin. A summary of the results of the outer
membrane permeabilization experiments are shown in Figure 4A. The C18G, C18G-Arg, and
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Figure 4. E. coli membrane permeabilization. Chromogenic substrate breakdown after 30 min of
Figure 4. E. coli membrane permeabilization. Chromogenic substrate breakdown after 30 min of
exposure to peptides. (A) Outer membrane permeabilization assayed by nitrocefin breakdown. (B)
exposure to peptides. (A) Outer membrane permeabilization assayed by nitrocefin breakdown.
Inner membrane permeabilization assayed by ONPG breakdown. In both panels colors represent
(B) Inner membrane permeabilization assayed by ONPG breakdown. In both panels colors represent
C18G (green), C18G-Arg (red), C18G-His (gray), C18G-Orn (orange), C18G-Dap (blue). All data is the
average of at least 3 replicates, where error bars represent the standard deviation.

Molecules 2018, 23, 329

8 of 17

Permeabilization of the E. coli inner membrane is monitored with the cytoplasmic enzyme
β-galactosidase and the chromogenic substrate ortho-nitrophenyl-β-galactoside (ONPG). This assay
in conceptually similar to the outer membrane assay described above, but is focused only on the
permeability of the inner membrane. The results are shown in Figure 4B for the 30 min time
point of the assay, and the full time course is shown in the supplementary figures (Figure S2).
Molecules 2018, 23, x
8 of 16
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Figure 5. Membrane permeabilization. (A) Permeabilization of S. aureus membranes by peptides.
Cultures of S. aureus were incubated with varying concentrations of peptide and 3.75 µg/mL
propidium iodide (PI). PI fluorescence was measured via flow cytometry after 30 min of exposure to
peptides. Percent leakage was determined based on the positive control CTAB (data not shown).
(B) Peptide induced hemolysis. Defibrinated sheep red blood cells were incubated for 1 h with
varying concentrations of peptide or control at 37 ◦ C in sterile PBS. After pelleting the remaining
cells, the absorbance of the supernatant was measured at 415 nm to detect released hemoglobin.
Percent leakage was determined based on the positive control CTAB (Figure S3). All data is the average
of at least 3 replicates, where error bars represent the standard deviation.

2.7. Hemolysis
Considering the membrane-active mechanism of many AMPs and the work presented earlier,
it became evident that the membrane permeabilizing action against mammalian cells was also
important to investigate. Using a well characterized hemolysis assay, the ability of the peptides
to disrupt or damage sheep red blood cells (RBCs) was measured. Briefly, the peptides are mixed
with defibrinated blood, incubated, and then centrifuged to collect the intact RBCs. The absorbance of
the supernatant is then measured at 415 nm, corresponding to the absorbance of hemoglobin. If the
peptides disrupt the membranes, hemoglobin leaks out of the damaged RBCs into the supernatant.
Percent hemolysis is calculated in comparison to an untreated control (0%) and a control treated with
8 mM CTAB (100%). The results are shown in Figure 5B. Overall, the peptides induced hemolysis
to a very low extent, with the greatest hemolysis caused by the C18G sequence (~9%) at the highest
concentration tested (15 µM). The hemolysis induced by the control compound is shown in .
3. Discussion
AMPs are a widely studied system, due to the diversity of sequences found in nature,
high specificity, and broad-spectrum activity, and relative ease of synthesis. However, despite several
decades of work on these peptides, no clear consensus sequences are evident, nor are there tools that
can accurately predict or de novo design AMPs. Investigating these molecules from a more traditional
structure–activity relationship approach may help yield insights into the molecular mechanisms that
are important for function, and/or provide information translatable to the design of novel small
molecule therapeutics that retain the beneficial qualities of AMPs.
In most cases investigated here, the specific identity of the cationic side chains did not have
a significant effect on the behavior of the peptide. In almost all cases, the cationic variant peptides
retained similar antibacterial activity to the parent sequence, differing no more than 2-fold in MIC for
any single bacterial species (Table 2). This is supportive of the hypothesis that the cationic charge of
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the peptide is mainly involved in the initial binding event between the peptide and the bacterial cell
surface. However, there are clear nuances in the data that are important in the full understanding of
the structure–activity relationship in these AMPs.
One area of interest is the non-naturally proteinogenic amino acids used in this study, Orn and
Dap. Non-natural and non-proteinogenic amino acids have been of significant interest in both the
peptide design and pharmaceutical fields [39]. From the peptide design perspective, these amino acids
offer additional routes of studying structure–activity relationships, while from the medicinal chemistry
perspective, they provide a method of introducing functional groups that may be less susceptible to
natural proteolytic degradation or recognition by the immune system [37,40]. The hypothesis that
peptide penetration into the hydrophobic core of the bilayer is critical for membrane disruption and
peptide activity is therefore directly linked to side chain length, and thus, the maximum possible
depth the peptide can penetrate into the bilayer. The results presented here indicate that the use of
these amino acids as the cationic functionality does not significantly impact the antibacterial activity
(Table 2). However, in the case of C18G-Dap, the ability of the peptide to adopt an alpha-helix was
diminished, likely due to the close proximity of the charged side chain amine group to the backbone of
the peptide, as reported previously [38,41]. These findings are especially interesting because the effect
of shortening the cationic side chain is much less pronounced than that observed for the shortening of
the hydrophobic side chains in peptides or peptidomimetic polymers [32,42]. However, these results
contrast with the work of Palermo et al., who demonstrated that shortening the cationic side chains in
antimicrobial polymers had significant effects on antimicrobial activity [43]. One possible explanation
is the length difference in the polymer side chains in their study (C6–C2) present a slightly larger
difference in length than studied in the peptide system (C4–C1). Alternatively, the fact that the
peptide still adopts some helical conformation, judged by the CD spectra in Figure 3, may allow it to
penetrate deeper into the nonpolar bilayer core than that of an unstructured polymer [43]. Nonetheless,
the antimicrobial activity is more tolerant to changes in the length of the spacer in the cationic residues
than the hydrophobic residues, and thus, can potentially be exploited in next generation peptide or
peptidomimetic designs.
The identity of the functional group that imparts the cationic charge to the sidechain had
somewhat more pronounced effects. The Lys, Orn, and Dap side chains all contain primary amine
groups, while the Arg contains a guanidino group, and His contains an imidazole ring. The comparison
of these side chains is complicated by the differences in size/length, as well as the differences in the pKa
of the side chains. The guanidino group had no significant effect on the activity of the peptide, even
though similar functional groups improved activity in peptidomimetic arylamide foldamers [44,45].
The bidentate nature of the Arg guanidino group is thought to enhance the binding to the bacterial
membrane [46,47]. A modest enhancement of binding was observed comparing C18G to C18G-Arg;
however, it is unlikely that this is due to the amine vs guanidino difference, as the C18G-Arg had
similar binding behavior to C18G-Orn (amine) and C18G-His (imidazole). Additionally, the inclusion
of Arg in short peptides has been linked to the ability to cross bilayers without significant bilayer
disruption, as seen in cell penetrating peptides (CPPs) [48,49]. Based on the data, inclusion of Arg alone
does not impart the ability to cross bilayers without disruption, as seen from the C18G-Arg peptide
disruption of both E. coli and S. aureus membranes (Figures 4 and 5A). Notably, the C18G-Arg was the
most effective at disrupting S. aureus membranes, indicating there may be differences in peptide–lipid
interactions as a result of the different lipid compositions in the two bacteria. The data does show
a significant increase in binding to zwitterionic PC membranes compared to C18G, and all of the
peptides that contain primary amines as the cationic group. While the translocation of C18G-Arg was
not directly measured in comparison to the other peptides, the molecular discriminators between CPP
and AMP may also be linked to the non-cationic residues, which in the case of C18G, is primarily
hydrophobic groups.
Regarding His, at pH 7, the His side chains are neutral, thus removing the electrostatic driving
force for binding the anionic membrane, which is consistent with the diminished antibacterial
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activity of the C18G-His peptide. Nonetheless, the peptide was able to bind to model lipid vesicles
and induce some degree of membrane permeabilization. This binding is likely driven through the
hydrophobic forces and/or the polar uncharged imidazole with the anionic lipid headgroups, as well
as the remaining +1 charge on the peptide from the N-terminus. Interestingly, the C18G-His peptide
exhibited a small, but reproducible decrease in permeabilization of E. coli membranes at the highest
concentrations tested. This may indicate that the C18G-His is forming an oligomeric structure at higher
concentrations, which competes with membrane binding. This type of His-driven oligomerization at
neutral pH has been previously reported [50]. The work by Marquette et al. and by many other groups
on His-containing AMPs clearly show a pH dependence in peptide behavior and activity that would
be of great future interest in the development of the C18G peptide platform [51,52].
It should also be noted that the C18G parent sequence, and thus, all the derivative sequences
studied herein, are somewhat unique in that they contain only Leu residues as the hydrophobic groups.
The original development of the C18G sequence was based on the C-terminal fragment of platelet factor
IV, and was modified to increase activity [27]. However, naturally occurring AMPs often have a mixture
of hydrophobic amino acids in the sequence, and the membrane disruption by AMPs and mimetics
has been clearly linked to the overall hydrophobicity of the molecule [13,42,53,54]. Additionally,
a number of groups have demonstrated the position of both cationic and hydrophobic residues can
have significant impacts on the activity and selectivity of AMPs [55–59]. Taken together, these findings
may necessitate a much finer-grained approach to detailed structure–activity relationship studies in
AMPs. The role of the cationic residues in the context of specific hydrophobic amino acids may also
impact activity, such that the tolerance of cationic chain lengths may be significantly influenced by the
size and shape of the corresponding hydrophobes in the molecule.
Overall, the results show that there is flexibility in the cationic residues in antibacterial peptides.
The binding of the peptides to lipid bilayers is clearly influenced by electrostatic interactions in that
peptides bind to bilayers containing anionic lipids with higher affinity than zwitterionic bilayers.
Even the C18G-His peptide which has lower net charge at pH 7 compared to the other sequences
bound anionic bilayers with higher affinity than zwitterionic bilayers. However, the results also
show that binding to anionic bilayers does not inherently translate to antibacterial activity. This is not
surprising as there are numerous examples of peptide and protein sequences that bind to bilayers but
do not disrupt bilayer integrity [58,60–62]. A better predictor of antibacterial efficacy is the membrane
permeabilization assays. The trends observed in the outer membrane leakage assay correspond to the
trends observed in MIC analysis for E. coli, indicating these two properties may be linked.
4. Materials and Methods
4.1. Materials
Peptides were purchased from Anaspec (Fremont, CA, USA), Genscript (Piscataway, NJ, USA)
or synthesized in-house by solid phase FMOC-chemistry methods. In-house synthesized sequences
were synthesized on a CEM-Liberty microwave-assisted synthesizer using a rink-amide resin with
DMF as the main solvent and 20% piperidine in DMF as the deprotecting agent. Cleavage of
peptides from the resin was achieved using a standard mixture of 92.5:2.5:2.5:2.5 trifluoroacetic
acid (TFA)/H2 O/triisopropylsilane (TIPS)/ethanedithiol. Peptide products were separated from
the resin via filtration and precipitation in ice-cold diethyl ether. All peptides were purified by
reversed-phase HPLC (RP-HPLC) with a linear gradient of water and acetonitrile each containing
0.1% TFA. Separations were performed on a Jupiter 300 C4 column (Phenomenex). Peptide identity in
the HPLC fractions were confirmed by MALDI-TOF MS analysis performed by Bruker Daltonics
(Billerica, MA, USA). Lipids, (16:0–18:1) 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine
(POPC, PC), and (16:0–18:1) 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (POPG, PG),
were purchased from Avanti Polar Lipids (Alabaster, AL, USA), and stored as stocks in chloroform at
−20 ◦ C. The buffers used were PBS (150 mM NaCl, 50 mM Na2 HPO4 /NaH2 PO4 ; pH 7.0), 10× diluted
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PBS (for circular dichroism (CD) measurements), or Z-Buffer (0.1 M Na2 HPO4 /NaH2 PO4 , 10 mM KCl,
1 mM MgSO4 , 0.05 M β-mercaptoethanol, pH 7.0).
4.2. Bacterial Culturing
Each bacterial strain was streaked onto LB–Miller agar (BD-Difco, Franklin Lakes, NJ, USA) plates
from a frozen stock collection (E. coli D31 [63] S. aureus ATCC: 27660, B. subtilis ATCC: 6051, P. aeruginosa
PAO1 [17], and A. baumannii ATCC: 19606). After incubation to allow colony growth, plates stored in
a refrigerator at 4 ◦ C. Overnight cultures were inoculated with a single colony of each bacterial strain
into fresh LB or Mueller Hinton broth (MH, BD-Difco) in sterile glass test tubes. Inoculated samples
were placed in a 37 ◦ C shaking incubator (250 rpm) for ~18 h. After the overnight incubation, a 1:200
dilution of the culture was made in fresh LB or MH for use in subsequent experiments.
4.3. Minimal Inhibitory Concentration/Minimal Bactericidal Concentration Assays
Bacterial growth inhibition was investigated using the standard minimal inhibitory concentration
(MIC) assay [64]. Cultures of bacteria were grown as described above, subsequently diluted to
~105 cfu/mL in MH media. Subsequently, 90 µL of this diluted culture was added to wells of a sterile
96-well plate containing serially diluted aliquots of the peptides for a final volume in the well of 100 µL.
The plate was covered and incubated at 37 ◦ C for 18 h. After incubation the OD600 was measured
with a Spectramax M5 multimode plate reader. Next, the minimal bactericidal concentration (MBC)
was determined by taking 1 µL of culture from each well on the plate corresponding to peptide
concentrations at and above the MIC and plating on a fresh LB-agar plate. The plate incubated
overnight at 37 ◦ C, and MBC was determined from the presence or absence of growth on each spot.
4.4. Fluorescence Spectroscopy
Measurements were performed on a JY-Horiba fluoromax4 instrument with emission and
excitation slits set to 2.5 nm. For lipid binding/titration assays, samples were excited at 280 nm
with emission measured over the range of 300–400 nm. All samples contained 2 µM peptide and
were titrated with a lipid vesicle stock ranging in concentration from 1–2 mM. The barycenter of the
spectrum is an intensity-weighted average over the wavelengths measured, and ∆barycenter is the
difference between the barycenter of the sample lacking lipid, and that of a given sample [32,65].
Spectra were corrected for background and dilution.
Vesicles were prepared by drying appropriate volumes of lipid stocks in a glass test tube under
N2 flow. Further removal of solvent was accomplished by subjecting the lipid film to vacuum for
1 h. The lipid film was then rehydrated in PBS while vortexing. This suspension was sonicated in
a high-power bath sonicator (Avanti Lipids, Alabaster, AL, USA) for 20 min to yield small unilamellar
vesicles (SUVs). Sonicated SUVs typically range in size from 20–60 nm in diameter [66,67].
4.5. Circular Dichroism Spectroscopy
CD spectra were collected using a Jasco J-815 spectropolarimeter. Samples for CD spectroscopy
contained 5 µM peptide in 0.1× PBS or 0.1× PBS and either 200 µM lipid vesicles, 100 mM SDS, or 50%
(v/v) trifluoroethanol. All spectra shown are the average of 64–128 scans and were corrected for
backgrounds by subtracting the spectra of the samples lacking peptide.
Lipid vesicles for CD spectra were created using the ethanol dilution method [33]. Lipid films
were created as described above, but after vacuum the films were first dissolved in 10 µL of ethanol
and vortexed vigorously while adding the appropriate volume of PBS.
4.6. E. coli Outer Membrane Permeability Assay
Permeabilization of the E. coli outer membrane was performed as described previously [32]. Briefly,
a single colony of E. coli D31 was inoculated in LB Broth (Difco) containing 100 mg/mL ampicillin
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and allowed to grow at 37 ◦ C with shaking overnight. The culture was diluted 1:200 in LB-Amp and
incubated at 37 ◦ C until the OD600 was ~0.2. The culture was subsequently centrifuged at 2500 rpm for
15 min. The pellet was resuspended in an equal volume of PBS and added to a 96-well plate containing
serially diluted peptides or polymyxin B (positive control). Immediately before reading, nitrocefin was
added to the wells (final concentration 0.25 mg/mL) and mixed by pipetting. The sample absorbance
was measured at 486 nm for 90 min. All assays were performed at least in triplicate.
4.7. E. coli Inner Membrane Permeability Assay
Inner membrane permeabilization was performed as described previously [32]. The procedure
follows that of the outer membrane permeabilization assay, described above, with several modifications.
Bacteria were grown overnight in LB media lacking Amp, and dilutions were made in LB supplemented
with IPTG. Assay plates were prepared the same, except that cells were not centrifuged before the assay,
and were added to the plate directly in the culture medium. Positive control for the inner membrane
assay was the cationic detergent CTAB. The substrate was ONPG dissolved in Z-buffer added to a final
concentration 0.6 mg/mL in the wells. The sample absorbance was measured at 420 nm for 90 min.
All assays were performed at least in triplicate
4.8. S. aureus Membrane Permeability Assay
Flow cytometry was used to identify cell permeability by incorporation of propidium iodide (PI)
into S. aureus under various concentrations of CTAB detergent, C18G, C18G-Arg, C18G-His, C18G-Orn,
C18G-Dap peptides using a BD FACSCelesta flow cytometer. Approximately 10,000 cells per sample in
100 µL of PBS, permeabilization reagent, and PI 5.6 µM solution, were incubated for 30 min or 45 min
at 23 ◦ C counted in duplicate, and fluorescent signal was evaluated Ex 488 nm laser, Em 575 filter.
Percentage of cells found to be permeable for all samples was established by gating around cells on
histogram illustrating PI signal with known complete permeabilization CTAB 102 µM.
4.9. Hemolysis Assay
Defibrinated sheep blood was diluted 2-fold in sterile PBS and pelleted in a benchtop clinical
centrifuge for 10 min. The pellet was resuspended in PBS to the original volume, and this process
was repeated 3× such that the supernatant was no longer red/pink in color. The pellet containing
RBCs was resuspended in PBS to the original volume. Next, 135 µL of RBCs was added to the wells of
a round bottom 96-well plate, each well containing serially diluted peptides or the positive control
CTAB. The plate was incubated at 37 ◦ C with shaking for 1 h. The plate was then centrifuged to
pellet the remaining RBCs and 6 µL of the supernatant was transferred to a flat bottom 96-well plate
containing 94 µL PBS in each well. Absorbance was measured at 420 nm. Percent hemolysis was
calculated based on the absorbance in each well after subtraction of the absorbance in wells containing
no peptide, and then normalized against the absorbance in the highest concentration CTAB wells
(8 mM) taken as 100% lysis.
Supplementary Materials: The Supplementary Materials are available online.
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